
Editas Medicine, Inc.: updates and filings
Price
$2.17
November 13, 2026Market cap $335M
What Ploutos Investor adds for Editas Medicine
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 21% since Nov 9, 2026, when the 10-Q these figures come from was filed ($2.75 then, $2.17 on Nov 13, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 8, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
- 26TueDealMaterial agreement entered, other material eventsDocument
- 26TueOtherOther material eventsDocument
- 26TueOtherRegulation FD disclosure, other material eventsDocument
- 14ThuOtherRegulation FD disclosure, other material eventsDocument
- 5TueReportQuarterly report · for the period to Mar 31, 2026Document
- 5TueResultsResults of operationsDocument
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 8, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 9, 2026Shares registered for employeesFormS-8
- Sep 8, 2026FilingFormEFFECT
- Aug 31, 2026Shelf registration for future offeringsFormS-3
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operations, officer or director changeForm8-K
- Jul 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 18, 2026Shareholder voteForm8-K
- Jun 3, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 3, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 2, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 26, 2026Material agreement entered, other material eventsForm8-K
- May 26, 2026FilingFormS-3MEF
- May 26, 2026Other material eventsForm8-K
- May 26, 2026Regulation FD disclosure, other material eventsForm8-K
- May 14, 2026Regulation FD disclosure, other material eventsForm8-K
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- Apr 28, 2026Annual report to shareholdersFormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 8, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 9, 2026 | S-8 | Shares registered for employees | Document |
| Sep 8, 2026 | EFFECT | Filing | Document |
| Aug 31, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, officer or director change | Document |
| Jul 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 18, 2026 | 8-K | Shareholder vote | Document |
| Jun 3, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 3, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 2, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 26, 2026 | 8-K | Material agreement entered, other material events | Document |
| May 26, 2026 | S-3MEF | Filing | Document |
| May 26, 2026 | 8-K | Other material events | Document |
| May 26, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 14, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | ARS | Annual report to shareholders | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 18, 2015.
The full analysis
What do Editas Medicine's filings show?
The filings are where every one of Editas Medicine's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.